Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

9 Cardiology Headlines You Missed in Q2 2026

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

6 Cardiology Headlines You Missed in June 2026

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Q&A: GLP-1 Receptor Agonists and the Advent of CKM Syndrome, With Lawrence Leiter, MD

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

Elif Oral, MD, discusses the clinical implications of the recent data emphasizing metreleptin’s anti-drug antibodies and their llack of impact on efficacy.